ArriVent Biopharma releases corporate presentation on late-stage oncology pipeline led by firmonertinib in EGFR-mutant NSCLC

Reuters2026/08/12 20:36

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ArriVent highlighted firmonertinib as its lead program, targeting first-line EGFR exon 20 insertion mutant NSCLC under FDA Breakthrough Therapy Designation.
Enrollment completed in the global Phase 3 FURVENT study in first-line EGFR exon 20 insertion NSCLC, with 398 patients enrolled.
Global Phase 3 ALPACCA trial in first-line EGFR PACC mutant NSCLC targets 480 patients, comparing firmonertinib 240 mg vs osimertinib or afatinib.
Cash and cash equivalents totaled USD 373.1 million as of June 30, 2026.
ADC pipeline update included ARR-217 in Phase 1 for GI tumors, with ARR-002 cleared for a US Phase 1 start in solid tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ArriVent Biopharma releases corporate presentation on late-stage oncology pipeline led by firmonertinib in EGFR-mutant NSCLC

You may also like

Crypto prices